Insight Center: Blogs

Hedge Fund Troll Undeterred by Initial Setbacks

Author: Thomas J. Engellenner


Read the full post at Post-Grant Counsel

Hedge Fund Troll Undeterred by Initial Setbacks

Kyle Bass and his hedge funds, the Coalitions for Affordable Drugs LLC, have failed in several of their initial attempts to knock out drug patents. In two decisions handed down late last month, the Patent Trial and Appeal Board (PTAB) of the US Patent Office refused to initiate trials on two petitions filed by Bass to challenge two patents on Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra. Then on September 2, 2015 another one of the Bass Funds, the Coalition for Affordable Drugs (Series V), was also dealt a setback in its effort to invalidate Biogen’s patents on another multiple sclerosis drug, Tecfidera.

Data protection laws have changed, so we have revised our Privacy Policy.